Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-AB-3PRGD2 in Integrin αVβ3 Positive Tumors
NCT05013086Phase 1Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2021
- Primary completion
- Oct 2024
- Modality
- Alpha Emitters, Beta Emitters
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-AB-3PRGD2 in Neoplasm, sponsored by Peking Union Medical College Hospital. Primary endpoint: Standardized Uptake Value at 1 year. Started Oct 2021; status: recruiting.
02
Drugs
177Lu-AB-3PRGD2
03
Conditions
Neoplasm
Beyond the preview
Go deeper on NCT05013086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05013086.